News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SymBio Pharmaceuticals Raises $24M in Series E



2/28/2011 7:10:59 AM

BioCentury -- SymBio Pharmaceuticals Ltd. (Tokyo, Japan) raised Y2 billion ($24 million) in a series E round led by existing investors Cephalon Inc. (NASDAQ:CEPH) and JAFCO. Last December, SymBio launched Treakisym bendamustine (SyB L-0501) in Japan to treat refractory and relapsed indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma. SymBio said it plans to develop the alkylating agent for other hematological indications, including aggressive NHL and multiple myeloma.

Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES